| Maryam Abdullah, | |
|
23 Mass Ave, Arlington, MA 02474-8602 | |
| (781) 648-0557 | |
| Not Available |
| Full Name | Maryam Abdullah |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 23 Mass Ave, Arlington, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144808361 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PH240067 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Maryam Abdullah, 82 Nyack St, Watertown, MA 02472-3110 Ph: () - | Maryam Abdullah, 23 Mass Ave, Arlington, MA 02474-8602 Ph: (781) 648-0557 |
News Archive
Oligonucleotide-based therapeutics present unique challenges when it comes to testing their potential to cause reproductive and developmental harm. New consensus guidelines for toxicity testing that take into consideration the combined chemical and biological characteristics of these novel biopharmaceuticals are presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Following a total joint replacement, anticoagulation (blood thinning) drugs can prevent Deep Vein Thrombosis (DVT), a blood clot deep within the extremities, or a pulmonary embolism (PE), a complication that causes a blood clot to move to the lungs.
Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of cancer, and that some patients can benefit by receiving precision drugs targeted to their tumors' mutations or being enrolled in clinical trials.
Sepsis is the leading cause of in-hospital death and there is no specific treatment for it. Now, research led by Dr. Qingping Feng of Western University (London, Canada) suggests a protein called recombinant human annexin A5 may have therapeutic potential for the treatment of this disease. The paper is published in advance, online in Critical Care Medicine.
Nabi Biopharmaceuticals today announced its second quarter financial results for the three month period ended June 26, 2010. The Company reported a net loss from continuing operations of $3.4 million, or $0.08 per share, compared to a net loss of $5.8 million, or $0.11 per share, for the period ended June 27, 2009.
› Verified 9 days ago
Mr. Darren S Johnhope, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 324 Mass Ave, Arlington, MA 02474 Phone: 978-761-9898 | |
Mr. Lawrence Guy Maida, REG PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 121 Mass Ave, Arlington, MA 02474 Phone: 781-643-7840 Fax: 781-643-0174 | |
Elizabeth Gultom, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 324 Massachusetts Ave, Arlington, MA 02474 Phone: 781-643-4112 | |
Ms. Petrece Marie Palmese, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1425 Massachusetts Ave, Arlington, MA 02476 Phone: 781-646-3869 | |
Lynn Vinh Diep, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 833 Massachusetts Ave, Arlington, MA 02476 Phone: 781-643-4272 | |
Celine Kim, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 324 Massachusetts Ave, Arlington, MA 02474 Phone: 781-643-4112 | |
Riley Ray Arsenault, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 833 Massachusetts Ave, Arlington, MA 02476 Phone: 781-643-4272 |